Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis
Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) an...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2020-10, Vol.99 (40), p.e21871-e21871 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e21871 |
|---|---|
| container_issue | 40 |
| container_start_page | e21871 |
| container_title | Medicine (Baltimore) |
| container_volume | 99 |
| creator | Wang, HongZhou Wang, WanHua Shi, HaiCun Han, LiJian Pan, PingLei |
| description | Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) and atypical parkinsonisms. However, blood NfL levels in these parkinsonisms from existing literature were inconsistent. No comprehensive meta-analysis has ever been conducted.
Three major biomedical electronic databases PubMed, Embase, and Web of Science were comprehensively searched from inception to July 10, 2020. This protocol will be prepared based on the guidelines recommended by the statement of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). Original observational studies that measured blood (serum/plasma) NfL concentrations in patients with parkinsonisms (multiple system atrophy [MSA], progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and dementia with Lewy bodies [DLB]), and healthy controls (HCs) will be included. Quality assessment of the included studies will be performed using the Newcastle Ottawa Scale (NOS). Meta-analyses will be conducted using the STATA software version 13.0. The standardized mean differences as the measure of effect size and 95% confidence intervals were calculated for each comparison of blood NfL levels. Heterogeneity analysis, sensitivity analysis, publication bias, subgroup analysis, and meta-regression analysis will be carried out to test the robustness of the results.
The meta-analysis will obtain the effect sizes of blood NfL levels in the following comparisons: PD versus HC, MSA versus HC, PSP versus HC, CBS versus HC, DLB versus HC, MSA versus PD, PSP versus PD, CBS versus PD, and DLB versus PD.
The present meta-analysis will provide the quantitative evidence of NfL levels in idiopathic PD and atypical parkinsonisms, hoping to facilitate differential diagnoses in clinical practice.
INPLASY202070091. |
| doi_str_mv | 10.1097/MD.0000000000021871 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448841706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3558-f1dea3f41b427699ba96bea73ac6ef7a7699e53d651fca419f6502627670b8fe3</originalsourceid><addsrcrecordid>eNpdkUtv1DAUhS0EokPhFyAhL9mk2PErYYHUBy1IrWABa-vGuemYOnGwk45mzR8n02nLw7Jk6dxzPts6hLzm7Iiz2ry7Ojtif1bJK8OfkBVXQheq1vIpWS2qKkxt5AF5kfMPxrgwpXxODoRgvBaVXpFfJyHGlg44p9j5AD0OEw3-ej1RtwY_0GV_hXTjhxwH2vqMkJHC0FKYtqN3EOj4MPa5z-_pMR1TnKKLgXYx0bzNE_YweUcT3nrc3IV7nKCAAcI2-_ySPOsgZHx1fx6S7-cfv51-Ki6_XHw-Pb4snFCqKjreIohO8kaWRtd1A7VuEIwAp7EzsNNQiVYr3jmQvO60YqVevIY1VYfikHzYc8e56bF1y1cTBDsm30Pa2gje_jsZ_Npex1trlFBa6gXw9h6Q4s8Z82R7nx2GAAPGOdtSyqqS3LCdVeytLsWcE3aP13Bmd_XZqzP7f31L6s3fL3zMPPS1GOTesIlhwpRvwrzBZNcIYVrf8ZSpy6JkJeMLlBU7qRK_AVIAqQc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448841706</pqid></control><display><type>article</type><title>Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wang, HongZhou ; Wang, WanHua ; Shi, HaiCun ; Han, LiJian ; Pan, PingLei</creator><creatorcontrib>Wang, HongZhou ; Wang, WanHua ; Shi, HaiCun ; Han, LiJian ; Pan, PingLei</creatorcontrib><description>Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) and atypical parkinsonisms. However, blood NfL levels in these parkinsonisms from existing literature were inconsistent. No comprehensive meta-analysis has ever been conducted.
Three major biomedical electronic databases PubMed, Embase, and Web of Science were comprehensively searched from inception to July 10, 2020. This protocol will be prepared based on the guidelines recommended by the statement of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). Original observational studies that measured blood (serum/plasma) NfL concentrations in patients with parkinsonisms (multiple system atrophy [MSA], progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and dementia with Lewy bodies [DLB]), and healthy controls (HCs) will be included. Quality assessment of the included studies will be performed using the Newcastle Ottawa Scale (NOS). Meta-analyses will be conducted using the STATA software version 13.0. The standardized mean differences as the measure of effect size and 95% confidence intervals were calculated for each comparison of blood NfL levels. Heterogeneity analysis, sensitivity analysis, publication bias, subgroup analysis, and meta-regression analysis will be carried out to test the robustness of the results.
The meta-analysis will obtain the effect sizes of blood NfL levels in the following comparisons: PD versus HC, MSA versus HC, PSP versus HC, CBS versus HC, DLB versus HC, MSA versus PD, PSP versus PD, CBS versus PD, and DLB versus PD.
The present meta-analysis will provide the quantitative evidence of NfL levels in idiopathic PD and atypical parkinsonisms, hoping to facilitate differential diagnoses in clinical practice.
INPLASY202070091.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000021871</identifier><identifier>PMID: 33019386</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Biomarkers - blood ; Humans ; Meta-Analysis as Topic ; Neurofilament Proteins - blood ; Parkinson Disease - blood ; Study Protocol Systematic Review ; Systematic Reviews as Topic</subject><ispartof>Medicine (Baltimore), 2020-10, Vol.99 (40), p.e21871-e21871</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3558-f1dea3f41b427699ba96bea73ac6ef7a7699e53d651fca419f6502627670b8fe3</cites><orcidid>0000-0003-2398-3700</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535646/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535646/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33019386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, HongZhou</creatorcontrib><creatorcontrib>Wang, WanHua</creatorcontrib><creatorcontrib>Shi, HaiCun</creatorcontrib><creatorcontrib>Han, LiJian</creatorcontrib><creatorcontrib>Pan, PingLei</creatorcontrib><title>Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) and atypical parkinsonisms. However, blood NfL levels in these parkinsonisms from existing literature were inconsistent. No comprehensive meta-analysis has ever been conducted.
Three major biomedical electronic databases PubMed, Embase, and Web of Science were comprehensively searched from inception to July 10, 2020. This protocol will be prepared based on the guidelines recommended by the statement of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). Original observational studies that measured blood (serum/plasma) NfL concentrations in patients with parkinsonisms (multiple system atrophy [MSA], progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and dementia with Lewy bodies [DLB]), and healthy controls (HCs) will be included. Quality assessment of the included studies will be performed using the Newcastle Ottawa Scale (NOS). Meta-analyses will be conducted using the STATA software version 13.0. The standardized mean differences as the measure of effect size and 95% confidence intervals were calculated for each comparison of blood NfL levels. Heterogeneity analysis, sensitivity analysis, publication bias, subgroup analysis, and meta-regression analysis will be carried out to test the robustness of the results.
The meta-analysis will obtain the effect sizes of blood NfL levels in the following comparisons: PD versus HC, MSA versus HC, PSP versus HC, CBS versus HC, DLB versus HC, MSA versus PD, PSP versus PD, CBS versus PD, and DLB versus PD.
The present meta-analysis will provide the quantitative evidence of NfL levels in idiopathic PD and atypical parkinsonisms, hoping to facilitate differential diagnoses in clinical practice.
INPLASY202070091.</description><subject>Biomarkers - blood</subject><subject>Humans</subject><subject>Meta-Analysis as Topic</subject><subject>Neurofilament Proteins - blood</subject><subject>Parkinson Disease - blood</subject><subject>Study Protocol Systematic Review</subject><subject>Systematic Reviews as Topic</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1DAUhS0EokPhFyAhL9mk2PErYYHUBy1IrWABa-vGuemYOnGwk45mzR8n02nLw7Jk6dxzPts6hLzm7Iiz2ry7Ojtif1bJK8OfkBVXQheq1vIpWS2qKkxt5AF5kfMPxrgwpXxODoRgvBaVXpFfJyHGlg44p9j5AD0OEw3-ej1RtwY_0GV_hXTjhxwH2vqMkJHC0FKYtqN3EOj4MPa5z-_pMR1TnKKLgXYx0bzNE_YweUcT3nrc3IV7nKCAAcI2-_ySPOsgZHx1fx6S7-cfv51-Ki6_XHw-Pb4snFCqKjreIohO8kaWRtd1A7VuEIwAp7EzsNNQiVYr3jmQvO60YqVevIY1VYfikHzYc8e56bF1y1cTBDsm30Pa2gje_jsZ_Npex1trlFBa6gXw9h6Q4s8Z82R7nx2GAAPGOdtSyqqS3LCdVeytLsWcE3aP13Bmd_XZqzP7f31L6s3fL3zMPPS1GOTesIlhwpRvwrzBZNcIYVrf8ZSpy6JkJeMLlBU7qRK_AVIAqQc</recordid><startdate>20201002</startdate><enddate>20201002</enddate><creator>Wang, HongZhou</creator><creator>Wang, WanHua</creator><creator>Shi, HaiCun</creator><creator>Han, LiJian</creator><creator>Pan, PingLei</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2398-3700</orcidid></search><sort><creationdate>20201002</creationdate><title>Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis</title><author>Wang, HongZhou ; Wang, WanHua ; Shi, HaiCun ; Han, LiJian ; Pan, PingLei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3558-f1dea3f41b427699ba96bea73ac6ef7a7699e53d651fca419f6502627670b8fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers - blood</topic><topic>Humans</topic><topic>Meta-Analysis as Topic</topic><topic>Neurofilament Proteins - blood</topic><topic>Parkinson Disease - blood</topic><topic>Study Protocol Systematic Review</topic><topic>Systematic Reviews as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, HongZhou</creatorcontrib><creatorcontrib>Wang, WanHua</creatorcontrib><creatorcontrib>Shi, HaiCun</creatorcontrib><creatorcontrib>Han, LiJian</creatorcontrib><creatorcontrib>Pan, PingLei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, HongZhou</au><au>Wang, WanHua</au><au>Shi, HaiCun</au><au>Han, LiJian</au><au>Pan, PingLei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-10-02</date><risdate>2020</risdate><volume>99</volume><issue>40</issue><spage>e21871</spage><epage>e21871</epage><pages>e21871-e21871</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) and atypical parkinsonisms. However, blood NfL levels in these parkinsonisms from existing literature were inconsistent. No comprehensive meta-analysis has ever been conducted.
Three major biomedical electronic databases PubMed, Embase, and Web of Science were comprehensively searched from inception to July 10, 2020. This protocol will be prepared based on the guidelines recommended by the statement of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). Original observational studies that measured blood (serum/plasma) NfL concentrations in patients with parkinsonisms (multiple system atrophy [MSA], progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and dementia with Lewy bodies [DLB]), and healthy controls (HCs) will be included. Quality assessment of the included studies will be performed using the Newcastle Ottawa Scale (NOS). Meta-analyses will be conducted using the STATA software version 13.0. The standardized mean differences as the measure of effect size and 95% confidence intervals were calculated for each comparison of blood NfL levels. Heterogeneity analysis, sensitivity analysis, publication bias, subgroup analysis, and meta-regression analysis will be carried out to test the robustness of the results.
The meta-analysis will obtain the effect sizes of blood NfL levels in the following comparisons: PD versus HC, MSA versus HC, PSP versus HC, CBS versus HC, DLB versus HC, MSA versus PD, PSP versus PD, CBS versus PD, and DLB versus PD.
The present meta-analysis will provide the quantitative evidence of NfL levels in idiopathic PD and atypical parkinsonisms, hoping to facilitate differential diagnoses in clinical practice.
INPLASY202070091.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>33019386</pmid><doi>10.1097/MD.0000000000021871</doi><orcidid>https://orcid.org/0000-0003-2398-3700</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2020-10, Vol.99 (40), p.e21871-e21871 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535646 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Biomarkers - blood Humans Meta-Analysis as Topic Neurofilament Proteins - blood Parkinson Disease - blood Study Protocol Systematic Review Systematic Reviews as Topic |
| title | Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T15%3A47%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20neurofilament%20light%20chain%20in%20Parkinson%20disease%20and%20atypical%20parkinsonisms:%20A%20protocol%20for%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Wang,%20HongZhou&rft.date=2020-10-02&rft.volume=99&rft.issue=40&rft.spage=e21871&rft.epage=e21871&rft.pages=e21871-e21871&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000021871&rft_dat=%3Cproquest_pubme%3E2448841706%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448841706&rft_id=info:pmid/33019386&rfr_iscdi=true |